# Oyster Therapeutics funding rounds and investors

As of 10 Nov 2026, Oyster Therapeutics has raised $60M across 1 verified round on record; latest: $60 million Series A led by 4BIO Capital, announced 10 Nov 2026.

A pharmaceutical company developing next-generation targeted protein degraders with an initial focus on tau-driven diseases like Alzheimer’s

Website: https://4biocapital.com  
Headquarters: London, UK  
Page: https://fireround.dev/companies/oyster-therapeutics

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2026-11-10 | Series A | $60 million | 4BIO Capital | Actium Group, CE-Ventures, Eli Lilly, MGB Ventures, Mission BioCapital, Oxford Science Enterprises, Syncona, TOHO Ventures | [businesswire.com](https://www.businesswire.com/news/home/20261109552229/en/Kesmalea-Therapeutics-Announces-%2460-Million-Series-A-Financing-to-Advance-Next-Generation-Targeted-Protein-Degraders-for-Alzheimers-and-Other-Neurodegenerative-Diseases-and-Rebrands-as-Oyster-Therapeutics), [globenewswire.com](https://www.globenewswire.com/news-release/2026/11/10/3399164/0/en/4bio-capital-leads-60m-series-a-financing-of-oyster-therapeutics-formerly-kesmalea-therapeutics-to-advance-next-generation-targeted-protein-degraders-for-alzheimer-s-and-other-neur.html), [globenewswire.com](https://www.globenewswire.com/news-release/2026/11/10/3399164/0/en/4bio-capital-leads-60m-series-a-financing-of-oyster-therapeutics-formerly-kesmalea-therapeutics-to-advance-next-generation-targeted-protein-degraders-for-alzheimer-s-and-other-neur.html?pdf=1) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.